The Nanocarrier Landscape─Evaluating Key Drug Delivery Vehicles and Their Capabilities: A Translational Perspective

Abstract

The field of nanomedicine is currently in a revolutionary phase, propelled by the significant potential of nanoparticles, which offer several advantages over traditional drug delivery systems. The purpose of this paper is to aggregate contemporary knowledge of nanoparticles developed and applied in drug delivery across major disease classes. Accordingly, we offer, through a thorough search of the literature, a comprehensive overview of the prevalent nanoparticles used in drug delivery systems, covering polymeric, lipid-based, inorganic, and carbon-based nanoparticles, and discuss their advantages and limitations. This work primarily focuses on studies published in the last 5 years, aiming to provide an up-to-date assessment of the critical nanoparticles in drug delivery. Narratively, we synthesize a comprehensive overview of the state-of-the-art in nanocarrier technology, providing in-depth insights into the key nanoparticle types presented in the contemporary literature, their fundamental benefits, potential clinical applications, and limitations impeding their development and adoption. We note that there are gaps and opportunities for concerted efforts focused on developing biocompatible and biodegradable nanoparticles, establishing scalable and cost-effective manufacturing processes, and addressing regulatory challenges associated with nanoparticle-based drug delivery systems. These challenges persist despite the immense translational success of nanoparticle-based drug delivery systems and necessitate continued interdisciplinary research and cross-industry collaboration among scientists, clinicians, and regulatory bodies.

Keywords: biocompatibility; nanocarriers; nanoparticle drug delivery; personalized nanomedicine; theranostics; toxicity.

1

Schematic illustrations of a) Enhancement of the oral uptake of liraglutide through polylactide acid (PLA) nanoparticles. Reproduced with permission from ref . Copyright 2019 Elsevier Inc.; b) Active targeting and passive targeting of nanodelivery-based formulations in tumors. Reproduced from ref . Available under a CC-BY 4.0 license. Copyright 2023 Shi et al.; c) Benefits of curcumin encapsulation as CLEN. Reproduced from ref . Available under a CC-BY 4.0 license. Copyright 2020 Gupta et al.; d) Theranostic application of nanoparticles in cancer therapy and diagnosis of multifunctional carbon-based nanoparticles. Reproduced from ref . Copyright 2023 American Chemical Society.

2

Chemical structures and schematic representations of various nanoparticles utilized in drug delivery systems. a) Synthetic and natural Poly-NPs; b) b(1) Quintessential nanosphere and nanocapsule structures. Reproduced from ref . Available under a CC-BY 4.0 license. Copyright 2020 Baldim et al. b(2) A hydrophobic drug encapsulated within an amphiphilic Poly-Np to stabilize it in a hydrophilic solvent environment; c) Some lipids used to prepare LNPs; d) Types of LNPs. Adapted from ref . Available under a CC-BY 4.0 license. Copyright 2020 Baldim et al.; e) Inorganic nanoparticles; f) Possible modifications of a magnetic nanocarrier; g) Carbon-based nanoparticles; h) Structural features of key carbon-based nanocarriers. Reproduced from ref . Copyright 2023 American Chemical Society.

3

Illustrations of a) Smart nanoparticles’ multifunctional use in cancer management. Reproduced from ref . Available under a CC-BY 4.0 license. Copyright 2023 Sun et al.; b) The proposed mechanism of the selective anticancer activity of Ag NPs-CHI against breast cancer cells. Reproduced from ref . Available under a CC-BY 4.0 license. Copyright 2023 Abdellatif et al.; c) Antiparasitic applications of nanocarriers. Reproduced from ref . Available under a CC-BY 4.0 license. Copyright 2024 Huang et al.; d) Preparation of Ag–Bi@MSNs and its synergistic antibacterial effects. Reproduced with permission from ref . Copyright 2020 WILEY-VCH Verlag GmbH & Co.; e) Nanocarriers’ capacity to facilitate CNS drug delivery by crossing or bypassing the BBB. Reproduced from ref . Available under a CC-BY 4.0 license. Copyright 2021 Faiyaz et al.; f) Nano-Se as an efficient approach to treating HD demonstrated in a model. Reproduced from ref . Copyright 2019 American Chemical Society.

4

a) Sequence of biological barriers that nanoparticles must overcome for precise drug delivery. Reproduced from ref . Available under a CC-BY 4.0 license. Copyright 2022 Waheed et al.; b) A schematic illustration of nanotechnology applications in personalized medicine. Reproduced from ref . Available under a CC-BY 4.0 license. Copyright 2022 Alghamdi et al.; c) Nanotheranostic platform for combined therapeutic and diagnostic applications. Reproduced from ref . Available under a CC-BY 4.0 license. Copyright 2023 Kashyap et al.